FDA approves expanded use of Daytrana

DUBLIN The Food and Drug Administration has approved a drug made by Shire for treating attention deficit hyperactivity disorder in adolescents, Shire said Tuesday.

The FDA approved Daytrana (methylphenidate), a transdermal patch for treating ADHD in adolescents ages 13 to 17 years. The drug already had approval for treating ADHD in children ages 6 to 12 years.

“The FDA approval of Daytrana for adolescents now extends this medication option to an additional group of ADHD patients who may benefit from ADHD treatment delivered by a patch,” Shire SVP for the ADHD business unit Mike Yasick said. “This approval reinforces Shire’s commitment to providing a varied and comprehensive portfolio of medicines to meet he diverse needs of ADHD patients.”